Amgen Rethinks Ganitumab After Longshot Pancreatic Cancer Trial Fails
Executive Summary
Hopes for IGF-1R inhibitor ganitumab had not been high due to past flops for others in the class. But research in extensive stage small-cell lung cancer and KRAS wild-type metastatic colorectal cancer goes on, at least for now.